Lipaglyn (Saroglitazar) is a dual peroxisome proliferator-activated receptor (PPAR) agonist indicated for the...
- Vaccine development: the need for speed
- Lack of CMO availability threatens cell and gene therapy development
- Novaliq’s NovaTears+Omega-3 represents the first-in-class omega-3-containing eye drop for evaporative dry eye
- Surprisingly good Phase II results for ibudilast in progressive MS
- Tenapanor likely to makes waves in IBS-C space
Understanding Sucrose: Matching Sucrose Quality to Functional Need
Raw source (Cane vs Beet)-Cane derived generally has higher residual b-glucan load than beet derived sucrose, which can carry over into final product.
Soliris – Treatment for PNH, aHUS, gMG, and NMOSD
Soliris (eculizumab) is a drug indicated for the treatment of paroxysmal nocturnal haemoglobinuria (PNH), atypical haemolytic uremic syndrome (aHUS), generalised myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD).
Verzenio (abemaciclib) for the Treatment of Metastatic Breast Cancer
Verzenio (abemaciclib) is a cyclin-dependent kinases (CDK) 4 and 6 inhibitor indicated for the treatment of women with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.
Lipaglyn (Saroglitazar) for Treating Hypertriglycerdemia in Type II Diabetes
Lipaglyn (Saroglitazar) is a dual peroxisome proliferator-activated receptor (PPAR) agonist indicated for the treatment of hypertriglyceridemia in Type II diabetics.
May’s top news stories
Novartis reported that the first clinical trial in its Phase III PLATINUM programme for QMF149 has met primary and key secondary endpoints in people with inadequately controlled asthma; and The National Institute of Allergy and Infectious Diseases (NIAID) has reported findings from a Phase I/II clinical trial of Okairos’ AdCh3NSmut1/MVA-NSmut vaccine. Drugdevelopment-technology.com wraps up the key headlines from May 2019.
April’s top news stories
Chinese clinical-stage biopharmaceutical company I-Mab Biopharma and German biotech company MorphoSys have begun the first dosed Phase III clinical study to assess investigational human CD38 antibody TJ202/MOR202 in combination with lenalidomide in patients suffering from relapsed or refractory multiple myeloma; and A small clinical trial by researchers at the University of Edinburgh in the UK has showed that cilostazol and isosorbide mononitrate could prevent recurrence of stroke and vascular dementia. Drugdevelopment-technology.com wraps up the key headlines from April 2019.
Olumiant (baricitinib) for the Treatment of Moderate-to-Severe Rheumatoid Arthritis
Olumiant® (baricitinib) is one of the first once-daily oral selective JAK1 and JAK2 inhibitors for the treatment of moderate-to-severe active rheumatoid arthritis (RA).